Granules India Q2 FY27 slides: record revenue amid margin pressure

Granules India reported Q2 FY27 revenue of ₹15,600 million, up 20% year over year, and PAT of ₹1,818 million, up 39%, while gross margin contracted 134 bps to 64.4% amid higher input and logistics costs linked to West Asia tensions. The Gagillapur US FDA inspection produced 11 observations, which management called addressable; the EIR is pending, and management expects to respond within 15 business days and anticipates resolution in about 90–100 days. The company ended the quarter with net cash of ₹8,280 million and plans roughly ₹20,000 million of organic capex over 3–4 years, but its stock fell 2.27% to ₹820.7 as investors weighed the regulatory and margin risks against growth.

Analysis

The key debate is whether growth converts into durable free cash flow, not whether the quarter’s headline sales were strong. Sequential EBITDA-margin pressure and sharply lower quarterly operating cash flow make the near-term earnings-quality test more important than the reported PAT growth. The net-cash position improves financing flexibility, but it followed warrant proceeds; it should not be read as evidence that operating cash generation has already strengthened. Planned capex and the peptide build-out raise the hurdle for cash returns.

The Gagillapur observations are a discrete event risk: management’s characterization is not a substitute for the EIR and remediation outcome. A clean resolution on the stated timeline would reduce the regulatory discount; delay or a more serious FDA classification could affect customer confidence and constrain growth at a key site. The quarter’s 72% North American sales mix leaves the business exposed to US product pricing and regulatory execution, while the three sole-FTF opportunities are too distant and contingent to support near-term valuation assumptions. Five nearer launches may help, but controlled-substance approvals and launch timing need verification.

Contrarian read: the market may be focusing on the audit headline while underweighting freight/input-cost pass-through lag and working-capital absorption. Conversely, the large US addressable-market figure and complex-generic pipeline can encourage investors to capitalize speculative upside prematurely. Peptide CDMO remains an investment option, not yet a demonstrated earnings engine. No evidence here supports a high-conviction directional trade without valuation, consensus, and price-reaction context.

Key Decisions for Investors

• Stay neutral on Granules India ahead of the Gagillapur EIR; treat the stated 90–100-day resolution window as a catalyst, not an assured outcome. Reassess after the EIR and remediation details are independently confirmed.
• For the next 1–3 months, track gross/EBITDA margins, freight and input-cost recovery, and operating cash flow versus working-capital needs. If margins continue to compress or cash conversion weakens despite revenue growth, reduce exposure; stabilization would improve the quality of the growth case.
• Do not assign material near-term value to the three sole-FTF filings: commercialization is described as 2.5–3 years away and remains contingent on litigation and regulatory outcomes. Verify launch approvals and sales contribution from the nearer-term products before raising estimates.
• Keep peptide CDMO in the watch category until revenue growth is accompanied by improving segment losses and evidence of utilization/customer conversion. The planned investment increases execution and return-on-capital risk if demand ramps slowly.
• A conditional relative-value setup is long Granules India versus a broad Indian pharma exposure only after a satisfactory EIR and at least one quarter of margin/cash-flow stabilization; invalidate it on adverse FDA developments or continued sequential margin deterioration. Obtain current valuation and consensus data before sizing.